Picture Berlin Partner Hotspot for Startups 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 6676 | Ordered by Date (ascending)
1 2 3 ... 65 66 67  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Agilent–Univ Duisburg-Essen: analytical technology, 201804– collab with new Agilent sponsored Teaching + Research Center for Separation (TRC) at UDE
Araxa Biosciences–Velabs Therapeutics: investment, 202105 acquisition of Araxa by Velabs company renamed Veraxa Biotech GmbH
Cellestia Biotech–SEVERAL: investment, 201701 seed financing round Series C CHF5.2m from Sotio/PPF Group + private investors
Cellestia Biotech–SEVERAL: investment, <2017 seed financing round Series A CHF0.5m
Cellestia Biotech–SEVERAL: investment, <2017 seed financing round Series B CHF2.3m
Endomagnetics–SEVERAL: investment, 201807 financing round Series C $10m (£8m) led by new investor Draper Esprit
Epsilen Bio–San Raffaele: epigenetics, 202006– collab strategic incl license agreem for epigenetic sliencing technology with SR-Tiget
Immunai–VSC (US): public relations, 202005 service existent by VSC
MedinCell–Gates Foundation: grant, 201911– grant up to $19m over 4 years from Gates Foundation for developm of long-acting contraceptive mdc-WWM
Mind NRG–Minerva Neurosciences: investment, before 202008 acquisition of Mind NRG (CH) by Minerva Neurosciences
Neogene Therapeutics–W2O Group: public relations, 202009 service existent W2O Group is media contact
OTHER–Novartis: investment, 201401 acquisition of biologics manufacturing faciltiy in Longmont CO by AveXis
ProQR Therapeutics–SEVERAL: investment, 201711 public offering + concurrent direct offering $20.79m at $3.25/share
R-Biopharm–EuroProxima: research antibodies, 201710 acquisition of research antibody line from EuroProxima BV by Progen Biotechnik GmbH
SimplicityBio–TATAA Biocenter: biomarker services, 201610– collab product integration to offer complete biomarker solutions
Takeda–Enterome: gastrointestinal drug, 2016– collab drug discovery focussed on microbiome targets
Takeda–Enterome: sibofimloc, 201810– license + collab ww $50m upfront + $640m milestones developm + promotion ww of EB8018
Commonwealth Holdings–MassMutual: investment, 1990 acquisition $150m of Oppenheimer Management Corp from British & Commonwealth Holdings plc 1990-01-01
Brechbühler–Phenomenex: chromatography consumables, 1991–201708 distribution in Switzerland by Brechbühler TERMINATED 9/17 1991-01-01
Hoechst–Clariant: investment, 1997 acquisition of Hoechst Speciality Chemical Business by Clariant 1997-01-01
Eurofins–SEVERAL: investment, 199710 IPO 1997-10-24
Boehringer Mannheim–Roche: investment, 1998 acquisition by Roche 1998-01-01
Biocentric–Hain Lifescience: molecular diagnostics, 2001– exclusive distributor of Hain products in France 2001-01-01
Per-Form Hungária–Danaher: mass spectrometer, 201909 existent distributor for Sciex technology in Hungary since 2001 2001-01-01
Selexis–SEVERAL: investment, 2001 seed financing CHF100k 2001-01-01
Grabner Instruments–Chandler Instruments: investment, 2002 acquisition of Grabner by Chandler 2002-01-01
Chandler Instruments–AMETEK: investment, 2003 acquisition of Chandler Instruments by AMETEK 2003-01-01
UCB–Amgen: therapeutic antibodies, 2004– collab + license r+d + marketing antibody products targeting protein sclerostin 2004-01-01
Actelion–Enamine: chemical compound library, 2005– collab supply of screening compound library to Actelion 2005-01-01
UroGène–Pierre Fabre: investment, 2005 acquisition of UroGène by Groupe Pierre Fabre 2005-01-01
EOS Imaging–LCF Rothschild: investment, 200511 investment by EdRIP 2005-11-01
ExpreS2ion Biotech–SEVERAL: investment, 201606–201607 IPO SEK19.2m (€2m) ca 3m new shares representing 35% of total capital at Nasdaq First North 2006-01-01
Umetrics–MKS Instruments: investment, 2006 acquisition by MKS Instruments 2006-01-01
Servier–Vernalis: cancer drugs, 2007– collab fragment + structure-based drug discovery 2007-01-01
BioNTech–SEVERAL: investment, 2008 seed financing round 2008-01-01
ClinPhone–Parexel: investment, 2008 acquisition of ClinPhone by Parexel 2008-01-01
Genmab–Eatwell D: management, 2008–202002 CFO RESIGNED 3/20 2008-01-01
Isoprime–Elementar: investment, 2008 acquisition of Isoprime Ltd by Elementar Analysensysteme GmbH 2008-01-01
KLIFO–PERSON: investment, 2008 acquisition of KLIFO A/S by Alejandra Mørk who joins as CEO 2008-01-01
Reapplix–SEED Capital: investment, 2008 founding investor SEED Capital 2008-01-01
Peplin–Leo Pharma: investment, 2009 acquisition of Peplin Inc by Leo Pharma A/S 2009-01-01
Sanofi–Oxford BioMedica: ophthalmic gene therapy, 2009–201902c collab developm + commerc Sanofi SEEKS NEW PARTNERS 2/19 2009-01-01
Probiodrug–Bellevue: investment, 200911 financing round Series B totalling €36m incl new + lead investors BB Biotech + EdRIP 2009-11-02
Probiodrug–Biogen Idec: investment, 200911 financing round Series B totalling €36m incl new + co-investor Biogen Idec New Ventures 2009-11-02
Probiodrug–LCF Rothschild: investment, 200911 financing round Series B totalling €36m incl new + lead investors BB Biotech + EdRIP 2009-11-02
Probiodrug–Life Sciences Partners: investment, 200911 financing round Series B totalling €36m incl new + co-investor LSP 2009-11-02
China National Nuclear–ITM Isotopen Technologien München: radiopharmaceuticals, 2010– collab strategic partnership with CIRC in China 2010-01-01
Ipsen–Syntaxin: rec botulinum toxin, 2010– collab initial agreement 2010-01-01
Shionogi–Stallergenes: antiallergic, 2010– collab developm + registration + marketing in JP of immunotherapy tablets 2010-01-01
Roche–Novimmune: therapeutic antibody, 201007– excl license to discover + develop ABs targeting IL-17 pathway for autoimmune diseases Genentech 2010-07-01
Poxel–LCF Rothschild: investment, 201007 financing round Series A totalling €16m incl lead investor EdRIP 2010-07-08
Cellnovo–LCF Rothschild: investment, 201101 investment by EdRIP 2011-01-01
Chiesi–Charles River: drug discovery, 2011– collab strategic integrated respiratory drug discovery partnership 2011-01-01
Ipsen–Syntaxin: rec botulinum toxin, 2011– collab expansion into ww strategic partnership 2011-01-01
JnJ–Molecular Partners: DARPins, 2011–201610 collab + license DARPin targeting IL-13 + IL-17 against pulmonary disease TERMINATED 10/16 2011-01-01
Meiji Seika Kaisha–Newron: safinamide, 2011– license to develop + manufacture + commercialise safinamide in Asia to Meiji Seika Pharma 2011-01-01
Novagali Pharma–Santen: investment, 2011 acquisition of Novagali by Santen Pharma Japan 2011-01-01
Pfizer–Kohlberg Kravis Roberts: investment, 2011 acquisition of Capsugel from Pfizer by KKR 2011-01-01
Rebiotix–SEVERAL: investment, 2011 seed financing round $5m 2011-01-01
Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies 2011-01-01
Genoptix–Novartis: investment, 201701–201703 DIVESTMENT sale €na of Genoptix (excl biopharma business) to Ampersand + 1315 Capital + new managers 2011-01-24
SP Industries–Graham Partners: investment, 201103 acquisition by Graham Partners 2011-03-01
Acacia Pharma–Gilde Investment: investment, 201103 financing round Series A totalling $10m incl existing investor Gilde Healthcare 2011-03-31
Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures 2011-03-31
Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare 2011-03-31
Genmab–Seattle Genetics: antibody-drug conjugates, 201110– license + collab agreem using SG’s ADC technology with HuMax-TF antibody 2011-10-01
GSK–JnJ: therapeutic antibody, 201112– license + co-developm agreem for sirukumab w excl rights for GSK in America 2011-12-01
Gilupi–Viroad: investment, 2012 investment in connnection w strategic partnership making Viroad largest shareholder of Gilupi 2012-01-01
JnJ–Phenex: RORgt inhibitors, 2012– collab r+d up to $135m for chronic inflammatory + autoimmune disease w Janssen Biotech 2012-01-01
KBI BioPharma–Selexis: cell line development, 2012– supply service use of cell lines created using SUREtechnology platform by KBI 2012-01-01
Qtis/e–Xeltis: investment, 2012 merger of Qtis/e with Xeltis 2012-01-01
Selexys Pharmaceuticals–Novartis: investment, 201611 acquisition by Novartis for up to $665m upfront + acquisition + milestone payments 2012-01-01
Viroad–Gilupi: diagnostic device, 2012 collab strategic partnership incl investment making Viroad largest shareholder of Gilupi 2012-01-01
B Braun–CeGaT: personalised medicine, 201201– collab strategic partnership to expand + internationalise CeGaT’s business 2012-01-31
Action Pharma–Abbott: AP214, 201205 acquisition $110m of AP214 by Abbott 2012-05-01
Cristal Therapeutics–BioGeneration Ventures: investment, 201206 seed financing round incl new + co-lead investor BGV 2012-06-18
Cristal Therapeutics–SEVERAL: investment, 201206 seed financing round led by new investors BGV + Thuja Capital 2012-06-18
Cristal Therapeutics–Thuja Capital: investment, 201206 seed financing round incl new + co-lead investor Thuja Capital 2012-06-18
Cristal Therapeutics–Univ Utrecht: investment, 201206 seed financing round incl existing + co-investor Utrecht University Holdings 2012-06-18
JnJ–Genmab: daratumumab, 201208– license excl ww for developm + manufacture + comercialistion to Janssen Biotech Inc 2012-08-01
PlasmidFactory–Sirion Biotech: gene delivery technology, 201212– collab pronotion of AAV vectors for preclinical ersearch 2012-12-04
ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management 2013-01-01
BioNTech–MAB Discovery: antibody technology, 2013– collab mAb generation using technology of MAB Discovery 2013-01-01
Boehringer–Qiagen: molecular companion diagnostics, 2013 collab existent incl therascreen EGRF RGQ PCR Kit for Giotrif 2013-01-01
Kaiser Optical Systems–Endress+Hauser: investment, 2013 acquisition by Endress+Hauser 2013-01-01
Microphyt–SEVERAL: investment, 2013 funding round over €2m 2013-01-01
NeuroNova (SE)–Newron: investment, 2013 acquisition of NeuroNova by Newron 2013-01-01
Omthera Pharmaceuticals–Sofinnova: investment, –2013 existent investor Sofinnova Partners at time of sale to AstraZeneca 2013-01-01
Pfizer–Mission Therapeutics: DUB inhibitors, 202007– collab expansion with evaluation + option agreem for DUB target validation 2013-01-01
United States (govt)–Sanofi: sargramostim, 2013– BARDA contract $36.5m for late stage developm + procurement of Leukine for public health emergency 2013-01-01
Viroclinics Biosciences–Gilde Investment: investment, 2013–201708 Gilde Healthcare Services fund acquires majority share SOLD 8/17 2013-01-01
Celgene–Bluebird Bio: CAR-T cell therapy, 201303– collab development for cancer 2013-03-01
Allecra Therapeutics–EMBL: investment, 201304 financing round Series A totalling €15m incl co-investor EMBL Ventures 2013-04-18
Allecra Therapeutics–Forbion: investment, 201304 financing round Series A totalling €15m incl co-lead investor Forbion 2013-04-18
Allecra Therapeutics–LCF Rothschild: investment, 201304 financing round Series A totalling €15m incl co-lead investor EdRIP 2013-04-18
Complix–Gimv: investment, 201306 financing round Series B totalling €12m incl new + co-lead investor Gimv w Biotech Fund Flanders 2013-06-26
Complix–LCF Rothschild: investment, 201306 financing round Series B totalling €12m incl new + co-lead investor EdRIP 2013-06-26
Advanced Liquid Logic–CEA: microfluidics technology, 201307 before license from CEA for EWOD microfluidics technology 2013-07-01
Cristal Therapeutics–Limburg (NL) (govt): investment, 201307 seed financing round expansion with Nedermaas Ventures + Innovatie Fonds Limburg 2013-07-01
Chiesi–Uniqure: gene therapy, 201307–201707 collab developm + commercialisation of hemophila B gene therapy TERMINATED 7/17 2013-07-09
1 2 3 ... 65 66 67  next pagenext page


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC C Lee Hood Speaking 650x300px

» top